Stock Events

Mindset Pharma 

C$0.74
4
+C$0+0% Thursday 16:33

Statistics

Day High
0.74
Day Low
0.74
52W High
0.75
52W Low
0.22
Volume
27,610
Avg. Volume
169,842
Mkt Cap
26.84M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

23FebExpected
Q3 2021
Q4 2021
Q1 2022
Q3 2022
Q4 2022
-0.08
-0.05
-0.03
-0.01
Expected EPS
-0.01
Actual EPS
-0.02

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MSET.CN. It's not an investment recommendation.
Alphabet
77346
GOOGL
Apple
67415
AAPL
Microsoft
62824
MSFT
Amazon
58558
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap511.54M
Compass Pathways operates in the psychedelic medicine sector, focusing on psilocybin therapy for depression, similar to Mindset Pharma's focus on psychedelic treatments.
ATAI Life Sciences N.V.
ATAI
Mkt Cap218.14M
ATAI Life Sciences works on developing psychedelic and non-psychedelic compounds for mental health disorders, directly competing with Mindset Pharma's psychedelic-based therapies.
Mind Medicine
MNMD
Mkt Cap493.47M
MindMed develops therapies from psychedelic substances including LSD, MDMA, and psilocybin, targeting the same mental health applications as Mindset Pharma.
Cybin
CYBN
Mkt Cap194.47M
Cybin Inc. focuses on developing psychedelic pharmaceuticals for mental health conditions, paralleling Mindset Pharma's objectives in the psychedelic space.
GH Research
GHRS
Mkt Cap546.3M
GH Research is developing a novel drug for treatment-resistant depression using 5-MeO-DMT, a psychedelic compound, which is a direct competitor to Mindset Pharma's psychedelic research.
Revive Therapeutics
RVVTF
Mkt Cap3.99M
Revive Therapeutics explores the use of psychedelics in treatments for various ailments, including mental health disorders, competing with Mindset Pharma's research and development in psychedelics.
Mydecine Innovations Group
MYCOF
Mkt Cap649,542
Mydecine Innovations Group focuses on developing and commercializing psychedelic medicines, including therapies for mental health, directly competing with Mindset Pharma's product pipeline.

About

Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. It focuses on developing MSP-1014, a psychedelic drug candidate. The company is based in Toronto, Canada.
Show more...
CEO
Mr. James Andre-Charles Lanthier
Country
CA
ISIN
CA60268M1023

Listings

CN
CA
MSET.CN